Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.94 and traded as high as $2.13. Protagenic Therapeutics shares last traded at $2.04, with a volume of 4,972 shares.
Protagenic Therapeutics Stock Performance
The company has a 50 day simple moving average of $1.80 and a 200 day simple moving average of $0.94. The company has a market capitalization of $8.81 million, a PE ratio of -2.32 and a beta of 0.16.
Institutional Investors Weigh In On Protagenic Therapeutics
A hedge fund recently raised its stake in Protagenic Therapeutics stock. Renaissance Technologies LLC grew its stake in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 102,200 shares of the biotechnology company’s stock after purchasing an additional 41,800 shares during the period. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 3.47% of the stock is currently owned by hedge funds and other institutional investors.
About Protagenic Therapeutics
Protagenic Therapeutics, Inc operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations.
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.